


CLAIM AMENDMENTS

Please replace all prior versions and listings of claims with the amended claims as follows:

1-21. (previously canceled)

22. (currently amended) A compound of formula I:



wherein:

Z is oxygen or sulfur;

R¹ is hydrogen, -CHN₂, -R, -CH₂OR, -CH₂SR, or -CH₂Y;

R is a C₁₋₁₂ aliphatic, aryl, aralkyl, heterocyclyl, or heterocyclylalkyl ring, wherein each of these groups is optionally substituted, and wherein said heterocyclic ring is a three to nine membered saturated or unsaturated mono-, bi-, or tri-heterocyclic ring system wherein each ring contains up to three heteroatoms selected from O, N, or S;

Y is an electronegative leaving group selected from F, Cl, Br, I, arylsulfonyloxy, alkylsulfonyloxy, trifluoromethanesulfonyloxy, OR', SR', -OC=O(R'), or -OPO(R⁶)(R⁷);

wherein R' is an aliphatic group, an aryl group, an aralkyl group, a carbocyclic group, an alkyl carbocyclic group, a heterocyclic group, or an alkyl heterocyclic group;

wherein R⁶ and R⁷ are independently selected from R or OR;

R² is+

~~i) -CO₂H, or an ester, or an amide thereof, or R² is an isostere of said -CO₂H, or~~

~~ii) -CH₂CO₂H, or an ester, or an amide thereof, or R² is an isostere of said -CH₂CO₂H~~ CO₂H, CH₂CO₂H or C₁₋₆ alkyl

esters, C₃₋₁₀ cycloalkyl esters, or cholesterol esters thereof; or primary, secondary or tertiary amides thereof; wherein suitable substituents on the nitrogen of said amides includes one or more C₁₋₆ alkyl groups optionally substituted with N(R)₂ or 5-6 membered heterocyclic rings containing 1-2 heteroatoms; and wherein R is linear or branched C₁₋₁₂ aliphatic;

R³ is selected from H, a side chain of a natural α -amino acid, or a substituted or unsubstituted group having a molecular weight up to about 140 Daltons selected from aliphatic, aryl, aralkyl, heterocyclyl or heterocyclylalkyl ring wherein said heterocyclyl or heterocyclylalkyl ring is a three to nine membered saturated or unsaturated mono-, bi-, or tri-heterocyclic ring system wherein each ring contains up to three heteroatoms selected from O, N, or S; and

R⁴ and R⁵ taken together with the intervening nitrogen form a mono-, bi- or tricyclic hetero ring system having 1-6 heteroatoms selected from nitrogen, oxygen or sulfur;

wherein said ring system is optionally substituted with one or more groups independently selected from halogen, -R⁹, -OR⁹, -OH, -SH, -SR⁹, protected OH (such as acyloxy), phenyl (Ph), substituted Ph, -OPh, substituted -OPh, -NO₂, -CN, -NH₂, -NHR⁹, -N(R⁹)₂, -NHCOR⁹, -NHCONHR⁹, -NHCON(R⁹)₂, -NR⁹COR⁹, -NHCO₂R⁹, -CO₂R⁹, -CO₂H, -COR⁹, -CONHR⁹, -CON(R⁹)₂, -S(O)₂R⁹, -SONH₂, -S(O)R⁹, -SO₂NHR⁹, or -NHS(O)₂R⁹;

wherein each R⁹ is independently selected from an

aliphatic group or a substituted aliphatic group;





wherein the optional substituents on said C₁₋₁₂ aliphatic group or aryl, aralkyl, heterocyclyl, or heterocyclylalkyl ring is independently selected from, from halogen, -R¹¹, -OR¹¹, -OH, -SH, -SR¹¹, acyloxy, substituted or unsubstituted Ph or OPh, -NO₂, -CN, -NH₂, -NHR¹¹, -N(R¹¹)₂, -NHCOR¹¹, -NHCONHR¹¹, -NHCON(R¹¹)₂, -NR¹¹COR¹¹, -NHCO₂R¹¹, -CO₂R¹¹, -CO₂H, -COR¹¹, -CONHR¹¹, -CON(R¹¹)₂, -S(O)₂R¹¹, -SONH₂, -S(O)R¹¹, -SO₂NHR¹¹,







-NHS(O)₂R¹¹, =O, =S, =NNHR¹¹, =NNR¹¹₂, =N-OR¹¹, =NNHCOR¹¹,
=NNHCO₂R¹¹, =NNHSO₂R¹¹, or =NR¹¹; and








wherein each R¹¹ is independently selected from a C₁₋₁₂ aliphatic group or a substituted C₁₋₁₂ aliphatic group.



23-35. (previously canceled)

36. (previously amended) The compound of claim 22 wherein the compound is selected from those compounds listed in Table 1 below:


No.	Structure
12	
13	
14	
15	

No.	Structure
16	
17	
18	
19	
38	
39	

No.	Structure
40	 <chem>CC(C)OC(=O)Nc1cc(F)c(=O)c1C(=O)Oc2ccccc2N3C(=O)c4ccccc4O3</chem>
41	 <chem>CC(C)OC(=O)Nc1cc(F)c(=O)c1C(=O)Oc2ccccc2N3C(=O)c4ccccc4N3</chem>
42	 <chem>CC(C)OC(=O)Nc1cc(F)c(=O)c1C(=O)Oc2ccccc2N3C(=O)c4ccccc4N3C</chem>
43	 <chem>CC(C)OC(=O)Nc1cc(F)c(=O)c1C(=O)Oc2ccccc2N3C(=O)c4ccccc4N3C1CC1</chem>
44	 <chem>CC(C)OC(=O)Nc1cc(F)c(=O)c1C(=O)Oc2ccccc2N3C(=O)c4ccccc4C3=O</chem>
45	 <chem>CC(C)OC(=O)Nc1cc(F)c(=O)c1C(=O)Oc2ccccc2N3C(=O)c4ccccc4O3</chem>
46	 <chem>CC(C)OC(=O)Nc1cc(F)c(=O)c1C(=O)Oc2ccccc2N3C(=O)c4ccccc4S(=O)(=O)N3</chem>

No.	Structure
47	
48	

37. (previously amended) The compound of claim 22 wherein the compound is selected from the following:



38. (previously canceled)

39. (previously presented) The compound according to claim 22 wherein Z is oxygen.

40. (previously presented) The compound according to claim 22 wherein R¹ is hydrogen, -R, -CH₂OR, -CH₂SR, or -CH₂Y.

41. (currently amended) The compound according to claim 22 wherein R² is+

~~CO₂H, or an ester, or an amide thereof, or R² is an isostere of said CO₂H.~~

CO₂H, or C₁₋₆ alkyl esters, C₃₋₁₀ cycloalkyl esters, or cholesterol esters thereof; or primary, secondary or tertiary amides thereof; wherein suitable substituents on the nitrogen of said amides includes one or more C₁₋₆ alkyl groups optionally substituted with N(R)₂ or 5-6 membered heterocyclic rings containing 1-2 heteroatoms; and wherein R is linear or branched C₁₋₁₂ aliphatic.

42. (previously presented) The compound according to claim 22 wherein R³ is a group having a molecular weight up to 140 Daltons selected from aliphatic, aryl, aralkyl, heterocyclyl or heterocyclylalkyl ring wherein said heterocyclyl ring is a three to nine membered saturated or unsaturated mono-, bi-, or tri-heterocyclic ring system wherein each ring contains up to three heteroatoms selected from O, N, or S.

43. (previously presented) The compound according to claim 22 wherein R⁴ and R⁵ taken together with the intervening nitrogen form a mono-, bi- or tricyclic hetero ring system wherein each ring of the system has 5-7 ring atoms;

wherein said ring system is optionally substituted with one or more groups independently selected from halogen, -R⁹, -OR⁹, -OH, -SH, -SR⁹, protected OH (such as acyloxy), phenyl (Ph), substituted Ph, -OPh, substituted -OPh, -NO₂, -CN, -NH₂, -NHR⁹, -N(R⁹)₂, -NHCOR⁹, -NHCONHR⁹, -NHCON(R⁹)₂, -NR⁹COR⁹, -NHCO₂R⁹, -CO₂R⁹, -CO₂H, -COR⁹, -CONHR⁹, -CON(R⁹)₂, -S(O)₂R⁹, -SONH₂, -S(O)R⁹, -SO₂NHR⁹, or -NHS(O)₂R⁹; and

wherein each R⁹ is independently selected from an aliphatic group or a substituted aliphatic group.

44. (previously presented) The compound according to claim 22 wherein Z is oxygen; and wherein R¹ is hydrogen, -R, -CH₂OR, -CH₂SR, or -CH₂Y.

45. (currently amended) The compound according to claim 22 wherein Z is oxygen; and wherein R² is+

- ~~i) CO₂H, or an ester, or an amide thereof, or R² is an isostere of said CO₂H; or~~
- ~~ii) CH₂CO₂H, or an ester, or an amide thereof, or R² is an isostere of said CH₂CO₂H.~~

CO₂H, CH₂CO₂H or C₁₋₆ alkyl esters, C₃₋₁₀ cycloalkyl esters, or cholesterol esters thereof; or primary, secondary or tertiary amides thereof; wherein suitable substituents on the nitrogen of said amides includes one or more C₁₋₆ alkyl groups optionally substituted with N(R)₂ or 5-6 membered heterocyclic rings containing 1-2 heteroatoms; and wherein R is linear or branched C₁₋₁₂ aliphatic.

46. (previously presented) The compound according to claim 22 wherein Z is oxygen; and wherein R³ is a group having a molecular weight up to 140 Daltons selected from aliphatic, aryl, aralkyl, heterocyclyl or heterocyclylalkyl ring wherein said heterocyclyl ring is a three to nine membered saturated or unsaturated mono-, bi-, or tri-heterocyclic ring system wherein each ring contains up to three heteroatoms selected from O, N, or S.

47. (previously presented) The compound according to claim 22 wherein Z is oxygen; and wherein R⁴ and R⁵ taken together with the intervening nitrogen form a mono-, bi- or tricyclic hetero ring system wherein each ring of the system has 5-7 ring atoms;

wherein said ring system is optionally substituted with one or more groups independently selected from halogen, -R⁹, -OR⁹, -OH, -SH, -SR⁹, protected OH (such as acyloxy), phenyl (Ph), substituted Ph, -OPh, substituted -OPh, -NO₂, -CN,

$-\text{NH}_2$, $-\text{NHR}^9$, $-\text{N}(\text{R}^9)_2$, $-\text{NHCOR}^9$, $-\text{NHCONHR}^9$, $-\text{NHCON}(\text{R}^9)_2$,
 $-\text{NR}^9\text{COR}^9$, $-\text{NHCO}_2\text{R}^9$, $-\text{CO}_2\text{R}^9$, $-\text{CO}_2\text{H}$, $-\text{COR}^9$, $-\text{CONHR}^9$, $-\text{CON}(\text{R}^9)_2$,
 $-\text{S}(\text{O})_2\text{R}^9$, $-\text{SONH}_2$, $-\text{S}(\text{O})\text{R}^9$, $-\text{SO}_2\text{NHR}^9$, or $-\text{NHS}(\text{O})_2\text{R}^9$; and

wherein each R^9 is independently selected from an aliphatic group or a substituted aliphatic group.

48. (currently amended) The compound according to claim 22 wherein R^1 is hydrogen, $-\text{R}$, $-\text{CH}_2\text{OR}$, $-\text{CH}_2\text{SR}$, or $-\text{CH}_2\text{Y}$; and wherein R^2 is+

~~i) CO_2H , or an ester, or an amide thereof, or R^2 is an isostere of said CO_2H ; or~~

~~ii) $\text{CH}_2\text{CO}_2\text{H}$, or an ester, or an amide thereof, or R^2 is an isostere of said $\text{CH}_2\text{CO}_2\text{H}$.~~

CO_2H , $\text{CH}_2\text{CO}_2\text{H}$ or C_{1-6} alkyl esters, C_{3-10} cycloalkyl esters, or cholesterol esters thereof; or primary, secondary or tertiary amides thereof; wherein suitable substituents on the nitrogen of said amides includes one or more C_{1-6} alkyl groups optionally substituted with $\text{N}(\text{R})_2$ or 5-6 membered heterocyclic rings containing 1-2 heteroatoms; and wherein R is linear or branched C_{1-12} aliphatic.

49. (previously presented) The compound according to claim 22 wherein R^1 is hydrogen, $-\text{R}$, $-\text{CH}_2\text{OR}$, $-\text{CH}_2\text{SR}$, or $-\text{CH}_2\text{Y}$; and wherein R^3 is a group having a molecular weight up to 140 Daltons selected from aliphatic, aryl, aralkyl, heterocyclyl or heterocyclylalkyl ring wherein said heterocyclyl ring is a three to nine membered saturated or unsaturated mono-, bi-, or tri-heterocyclic ring system wherein each ring contains up to three heteroatoms selected from O, N, or S.

50. (previously presented) The compound according to claim 22 wherein R^1 is hydrogen, $-\text{R}$, $-\text{CH}_2\text{OR}$, $-\text{CH}_2\text{SR}$, or $-\text{CH}_2\text{Y}$; and wherein R^4 and R^5 taken together with the intervening

nitrogen form a mono-, bi- or tricyclic hetero ring system wherein each ring of the system has 5-7 ring atoms;

wherein said ring system is optionally substituted with one or more groups independently selected from halogen, $-R^9$, $-OR^9$, $-OH$, $-SH$, $-SR^9$, protected OH (such as acyloxy), phenyl (Ph), substituted Ph, $-OPh$, substituted $-OPh$, $-NO_2$, $-CN$, $-NH_2$, $-NHR^9$, $-N(R^9)_2$, $-NHCOR^9$, $-NHCONHR^9$, $-NHCON(R^9)_2$, $-NR^9COR^9$, $-NHCO_2R^9$, $-CO_2R^9$, $-CO_2H$, $-COR^9$, $-CONHR^9$, $-CON(R^9)_2$, $-S(O)_2R^9$, $-SONH_2$, $-S(O)R^9$, $-SO_2NHR^9$, or $-NHS(O)_2R^9$; and

wherein each R^9 is independently selected from an aliphatic group or a substituted aliphatic group.

51. (previously presented) The compound according to claim 22 wherein R^2 is:

~~i) CO_2H , or an ester, or an amide thereof, or R^2 is an isostere of said CO_2H , or~~

~~ii) CH_2CO_2H , or an ester, or an amide thereof, or R^2 is an isostere of said CH_2CO_2H ; and~~

CO_2H , CH_2CO_2H or C_{1-6} alkyl esters, C_{3-10} cycloalkyl esters, or cholesterol esters thereof; or primary, secondary or tertiary amides thereof; wherein suitable substituents on the nitrogen of said amides includes one or more C_{1-6} alkyl groups optionally substituted with $N(R)_2$ or 5-6 membered heterocyclic rings containing 1-2 heteroatoms; and wherein R is linear or branched C_{1-12} aliphatic; and

wherein R^3 is a group having a molecular weight up to 140 Daltons selected from aliphatic, aryl, aralkyl, heterocyclyl or heterocyclylalkyl ring wherein said heterocyclyl ring is a three to nine membered saturated or unsaturated mono-, bi-, or tri-heterocyclic ring system wherein each ring contains up to three heteroatoms selected from O, N, or S.

52. (currently amended) The compound according to claim 22 wherein R^2 is:

~~i) CO_2H , or an ester, or an amide thereof, or R^2 is an isostere of said CO_2H ; or~~
~~ii) $\text{CH}_2\text{CO}_2\text{H}$, or an ester, or an amide thereof, or R^2 is an isostere of said $\text{CH}_2\text{CO}_2\text{H}$; and~~
 CO_2H , $\text{CH}_2\text{CO}_2\text{H}$ or C_{1-6} alkyl esters, C_{3-10} cycloalkyl esters, or cholesterol esters thereof; or primary, secondary or tertiary amides thereof; wherein suitable substituents on the nitrogen of said amides includes one or more C_{1-6} alkyl groups optionally substituted with $\text{N}(\text{R})_2$ or 5-6 membered heterocyclic rings containing 1-2 heteroatoms; and wherein R is linear or branched C_{1-12} aliphatic; and
wherein R^4 and R^5 taken together with the intervening nitrogen form a mono-, bi- or tricyclic hetero ring system wherein each ring of the system has 5-7 ring atoms;

wherein said ring system is optionally substituted with one or more groups independently selected from halogen, $-\text{R}^9$, $-\text{OR}^9$, $-\text{OH}$, $-\text{SH}$, $-\text{SR}^9$, protected OH (such as acyloxy), phenyl (Ph), substituted Ph, $-\text{OPh}$, substituted $-\text{OPh}$, $-\text{NO}_2$, $-\text{CN}$, $-\text{NH}_2$, $-\text{NHR}^9$, $-\text{N}(\text{R}^9)_2$, $-\text{NHCOR}^9$, $-\text{NHCONHR}^9$, $-\text{NHCON}(\text{R}^9)_2$, $-\text{NR}^9\text{COR}^9$, $-\text{NHCO}_2\text{R}^9$, $-\text{CO}_2\text{R}^9$, $-\text{CO}_2\text{H}$, $-\text{COR}^9$, $-\text{CONHR}^9$, $-\text{CON}(\text{R}^9)_2$, $-\text{S}(\text{O})_2\text{R}^9$, $-\text{SONH}_2$, $-\text{S}(\text{O})\text{R}^9$, $-\text{SO}_2\text{NHR}^9$, or $-\text{NHS}(\text{O})_2\text{R}^9$; and

wherein each R^9 is independently selected from an aliphatic group or a substituted aliphatic group.

53. (previously presented) The compound according to claim 22 wherein R^3 is a group having a molecular weight up to 140 Daltons selected from aliphatic, aryl, aralkyl, heterocyclyl or heterocyclylalkyl ring wherein said heterocyclyl ring is a three to nine membered saturated or unsaturated mono-, bi-, or tri-heterocyclic ring system wherein each ring contains up to three heteroatoms selected from O, N, or S; and

wherein R⁴ and R⁵ taken together with the intervening nitrogen form a mono-, bi- or tricyclic hetero ring system wherein each ring of the system has 5-7 ring atoms;

wherein said ring system is optionally substituted with one or more groups independently selected from halogen, -R⁹, -OR⁹, -OH, -SH, -SR⁹, protected OH (such as acyloxy), phenyl (Ph), substituted Ph, -OPh, substituted -OPh, -NO₂, -CN, -NH₂, -NHR⁹, -N(R⁹)₂, -NHCOR⁹, -NHCONHR⁹, -NHCON(R⁹)₂, -NR⁹COR⁹, -NHCO₂R⁹, -CO₂R⁹, -CO₂H, -COR⁹, -CONHR⁹, -CON(R⁹)₂, -S(O)₂R⁹, -SONH₂, -S(O)R⁹, -SO₂NHR⁹, or -NHS(O)₂R⁹; and

wherein each R⁹ is independently selected from an aliphatic group or a substituted aliphatic group.

54. (currently amended) The compound according to claim 22 wherein Z is oxygen;

wherein R¹ is hydrogen, -R, -CH₂OR, -CH₂SR, or -CH₂Y; and

wherein R² is:

~~i) -CO₂H, or an ester, or an amide thereof; or R² is an isostere of said -CO₂H; or~~

~~CH₂CO₂H, or an ester, or an amide thereof; or R² is an isostere of said -CH₂CO₂H.~~

CO₂H, CH₂CO₂H or C₁₋₆ alkyl esters, C₃₋₁₀ cycloalkyl esters, or cholesterol esters thereof; or primary, secondary or tertiary amides thereof; wherein suitable substituents on the nitrogen of said amides includes one or more C₁₋₆ alkyl groups optionally substituted with N(R)₂ or 5-6 membered heterocyclic rings containing 1-2 heteroatoms; and wherein R is linear or branched C₁₋₁₂ aliphatic.

55. (previously presented) The compound according to claim 22 wherein Z is oxygen;

wherein R¹ is hydrogen, -R, -CH₂OR, -CH₂SR, or -CH₂Y; and

wherein R³ is a group having a molecular weight up to 140

Daltons selected from aliphatic, aryl, aralkyl, heterocyclyl

or heterocyclalkyl ring wherein said heterocyclalkyl ring is a three to nine membered saturated or unsaturated mono-, bi-, or tri-heterocyclic ring system wherein each ring contains up to three heteroatoms selected from O, N, or S.

56. (previously presented) The compound according to claim 22 wherein Z is oxygen;
wherein R¹ is hydrogen, -R, -CH₂OR, -CH₂SR, or -CH₂Y; and
wherein R⁴ and R⁵ taken together with the intervening nitrogen form a mono-, bi- or tricyclic hetero ring system wherein each ring of the system has 5-7 ring atoms;

wherein said ring system is optionally substituted with one or more groups independently selected from halogen, -R⁹, -OR⁹, -OH, -SH, -SR⁹, protected OH (such as acyloxy), phenyl (Ph), substituted Ph, -OPh, substituted -OPh, -NO₂, -CN, -NH₂, -NHR⁹, -N(R⁹)₂, -NHCOR⁹, -NHCONHR⁹, -NHCON(R⁹)₂, -NR⁹COR⁹, -NHCO₂R⁹, -CO₂R⁹, -CO₂H, -COR⁹, -CONHR⁹, -CON(R⁹)₂, -S(O)₂R⁹, -SONH₂, -S(O)R⁹, -SO₂NHR⁹, or -NHS(O)₂R⁹; and

wherein each R⁹ is independently selected from an aliphatic group or a substituted aliphatic group.

57. (currently amended) The compound according to claim 22 wherein R¹ is hydrogen, -R, -CH₂OR, -CH₂SR, or -CH₂Y;
wherein R² is:

~~i) -CO₂H, or an ester, or an amide thereof, or R² is an isostere of said -CO₂H; or~~
~~CH₂CO₂H, or an ester, or an amide thereof, or R² is an isostere of said -CH₂CO₂H; and~~
CO₂H, CH₂CO₂H or C₁₋₆ alkyl esters, C₃₋₁₀ cycloalkyl esters, or cholesterol esters thereof; or primary, secondary or tertiary amides thereof; wherein suitable substituents on the nitrogen of said amides includes one or more C₁₋₆ alkyl groups optionally substituted with N(R)₂ or 5-6 membered heterocyclic

rings containing 1-2 heteroatoms; and wherein R is linear or branched C₁₋₁₂ aliphatic;

wherein R³ is a group having a molecular weight up to 140 Daltons selected from aliphatic, aryl, aralkyl, heterocyclyl or heterocyclylalkyl ring wherein said heterocyclyl ring is a three to nine membered saturated or unsaturated mono-, bi-, or tri-heterocyclic ring system wherein each ring contains up to three heteroatoms selected from O, N, or S.

58. (currently amended) The compound according to claim 22 wherein R¹ is hydrogen, -R, -CH₂OR, -CH₂SR, or -CH₂Y; wherein R² is:

~~i) -CO₂H, or an ester, or an amide thereof; or R² is an isostere of said -CO₂H; or~~

~~CH₂CO₂H, or an ester, or an amide thereof; or R² is an isostere of said CH₂CO₂H; and~~

CO₂H, CH₂CO₂H or C₁₋₆ alkyl esters, C₃₋₁₀ cycloalkyl esters, or cholesterol esters thereof; or primary, secondary or tertiary amides thereof; wherein suitable substituents on the nitrogen of said amides includes one or more C₁₋₆ alkyl groups optionally substituted with N(R)₂ or 5-6 membered heterocyclic rings containing 1-2 heteroatoms; and wherein R is linear or branched C₁₋₁₂ aliphatic; and

wherein R⁴ and R⁵ taken together with the intervening nitrogen form a mono-, bi- or tricyclic hetero ring system wherein each ring of the system has 5-7 ring atoms;

wherein said ring system is optionally substituted with one or more groups independently selected from halogen, -R⁹, -OR⁹, -OH, -SH, -SR⁹, protected OH (such as acyloxy), phenyl (Ph), substituted Ph, -OPh, substituted -OPh, -NO₂, -CN, -NH₂, -NHR⁹, -N(R⁹)₂, -NHCOR⁹, -NHCONHR⁹, -NHCON(R⁹)₂, -NR⁹COR⁹, -NHCO₂R⁹, -CO₂R⁹, -CO₂H, -COR⁹, -CONHR⁹, -CON(R⁹)₂, -S(O)₂R⁹, -SONH₂, -S(O)R⁹, -SO₂NHR⁹, or -NHS(O)₂R⁹; and

wherein each R^9 is independently selected from an aliphatic group or a substituted aliphatic group.

59. (previously presented) The compound according to claim 22 wherein R^1 is hydrogen, -R, $-CH_2OR$, $-CH_2SR$, or $-CH_2Y$; wherein R^3 is a group having a molecular weight up to 140 Daltons selected from aliphatic, aryl, aralkyl, heterocyclyl or heterocyclylalkyl ring wherein said heterocyclyl ring is a three to nine membered saturated or unsaturated mono-, bi-, or tri-heterocyclic ring system wherein each ring contains up to three heteroatoms selected from O, N, or S; and wherein R^4 and R^5 taken together with the intervening nitrogen form a mono-, bi- or tricyclic hetero ring system wherein each ring of the system has 5-7 ring atoms;

wherein said ring system is optionally substituted with one or more groups independently selected from halogen, $-R^9$, $-OR^9$, $-OH$, $-SH$, $-SR^9$, protected OH (such as acyloxy), phenyl (Ph), substituted Ph, $-OPh$, substituted $-OPh$, $-NO_2$, $-CN$, $-NH_2$, $-NHR^9$, $-N(R^9)_2$, $-NHCOR^9$, $-NHCONHR^9$, $-NHCON(R^9)_2$, $-NR^9COR^9$, $-NHCO_2R^9$, $-CO_2R^9$, $-CO_2H$, $-COR^9$, $-CONHR^9$, $-CON(R^9)_2$, $-S(O)_2R^9$, $-SONH_2$, $-S(O)R^9$, $-SO_2NHR^9$, or $-NHS(O)_2R^9$; and

wherein each R^9 is independently selected from an aliphatic group or a substituted aliphatic group.

60. (currently amended) The compound according to claim 22 wherein R^2 is:

~~i) $-CO_2H$, or an ester, or an amide thereof; or R^2 is an isostere of said $-CO_2H$; or CH_2CO_2H , or an ester, or an amide thereof; or R^2 is an isostere of said CH_2CO_2H ;~~

CO_2H , CH_2CO_2H or C_{1-6} alkyl esters, C_{3-10} cycloalkyl esters, or cholesterol esters thereof; or primary, secondary or tertiary amides thereof; wherein suitable substituents on the nitrogen of said amides includes one or more C_{1-6} alkyl groups

optionally substituted with N(R)₂ or 5-6 membered heterocyclic rings containing 1-2 heteroatoms; and wherein R is linear or branched C₁₋₁₂ aliphatic;

wherein R³ is a group having a molecular weight up to 140 Daltons selected from aliphatic, aryl, aralkyl, heterocyclyl or heterocyclylalkyl ring wherein said heterocyclyl ring is a three to nine membered saturated or unsaturated mono-, bi-, or tri-heterocyclic ring system wherein each ring contains up to three heteroatoms selected from O, N, or S; and wherein R⁴ and R⁵ taken together with the intervening nitrogen form a mono-, bi- or tricyclic hetero ring system wherein each ring of the system has 5-7 ring atoms;

wherein said ring system is optionally substituted with one or more groups independently selected from halogen, -R⁹, -OR⁹, -OH, -SH, -SR⁹, protected OH (such as acyloxy), phenyl (Ph), substituted Ph, -OPh, substituted -OPh, -NO₂, -CN, -NH₂, -NHR⁹, -N(R⁹)₂, -NHCOR⁹, -NHCONHR⁹, -NHCON(R⁹)₂, -NR⁹COR⁹, -NHCO₂R⁹, -CO₂R⁹, -CO₂H, -COR⁹, -CONHR⁹, -CON(R⁹)₂, -S(O)₂R⁹, -SONH₂, -S(O)R⁹, -SO₂NHR⁹, or -NHS(O)₂R⁹; and

wherein each R⁹ is independently selected from an aliphatic group or a substituted aliphatic group.

61. (currently amended) The compound according to claim 22 wherein Z is oxygen;

wherein R² is:

~~i) CO₂H, or an ester, or an amide thereof; or R² is an isostere of said CO₂H; or CH₂CO₂H, or an ester, or an amide thereof; or R² is an isostere of said CH₂CO₂H; and~~

CO₂H, CH₂CO₂H or C₁₋₆ alkyl esters, C₃₋₁₀ cycloalkyl esters, or cholesterol esters thereof; or primary, secondary or tertiary amides thereof; wherein suitable substituents on the nitrogen of said amides includes one or more C₁₋₆ alkyl groups optionally substituted with N(R)₂ or 5-6 membered heterocyclic

rings containing 1-2 heteroatoms; and wherein R is linear or branched C₁₋₁₂ aliphatic; and

wherein R³ is a group having a molecular weight up to 140 Daltons selected from aliphatic, aryl, aralkyl, heterocyclyl or heterocyclylalkyl ring wherein said heterocyclyl ring is a three to nine membered saturated or unsaturated mono-, bi-, or tri-heterocyclic ring system wherein each ring contains up to three heteroatoms selected from O, N, or S.

62. (currently amended) The compound according to claim 22 wherein Z is oxygen;

wherein R² is:

~~i) CO₂H, or an ester, or an amide thereof; or R² is an isostere of said CO₂H; or~~

~~CH₂CO₂H, or an ester, or an amide thereof; or R² is an isostere of said CH₂CO₂H; and~~

CO₂H, CH₂CO₂H or C₁₋₆ alkyl esters, C₃₋₁₀ cycloalkyl esters, or cholesterol esters thereof; or primary, secondary or tertiary amides thereof; wherein suitable substituents on the nitrogen of said amides includes one or more C₁₋₆ alkyl groups optionally substituted with N(R)₂ or 5-6 membered heterocyclic rings containing 1-2 heteroatoms; and wherein R is linear or branched C₁₋₁₂ aliphatic; and

wherein R⁴ and R⁵ taken together with the intervening nitrogen form a mono-, bi- or tricyclic hetero ring system wherein each ring of the system has 5-7 ring atoms;

wherein said ring system is optionally substituted with one or more groups independently selected from halogen, -R⁹, -OR⁹, -OH, -SH, -SR⁹, protected OH (such as acyloxy), phenyl (Ph), substituted Ph, -OPh, substituted -OPh, -NO₂, -CN, -NH₂, -NHR⁹, -N(R⁹)₂, -NHCOR⁹, -NHCONHR⁹, -NHCON(R⁹)₂, -NR⁹COR⁹, -NHCO₂R⁹, -CO₂R⁹, -CO₂H, -COR⁹, -CONHR⁹, -CON(R⁹)₂, -S(O)₂R⁹, -SONH₂, -S(O)R⁹, -SO₂NHR⁹, or -NHS(O)₂R⁹; and

wherein each R⁹ is independently selected from an aliphatic group or a substituted aliphatic group.

63. (previously presented) The compound according to claim 22 wherein Z is oxygen; wherein R³ is a group having a molecular weight up to 140 Daltons selected from aliphatic, aryl, aralkyl, heterocyclyl or heterocyclylalkyl ring wherein said heterocyclyl ring is a three to nine membered saturated or unsaturated mono-, bi-, or tri-heterocyclic ring system wherein each ring contains up to three heteroatoms selected from O, N, or S; and wherein R⁴ and R⁵ taken together with the intervening nitrogen form a mono-, bi- or tricyclic hetero ring system wherein each ring of the system has 5-7 ring atoms;

wherein said ring system is optionally substituted with one or more groups independently selected from halogen, -R⁹, -OR⁹, -OH, -SH, -SR⁹, protected OH (such as acyloxy), phenyl (Ph), substituted Ph, -OPh, substituted -OPh, -NO₂, -CN, -NH₂, -NHR⁹, -N(R⁹)₂, -NHCOR⁹, -NHCONHR⁹, -NHCON(R⁹)₂, -NR⁹COR⁹, -NHCO₂R⁹, -CO₂R⁹, -CO₂H, -COR⁹, -CONHR⁹, -CON(R⁹)₂, -S(O)₂R⁹, -SONH₂, -S(O)R⁹, -SO₂NHR⁹, or -NHS(O)₂R⁹; and

wherein each R⁹ is independently selected from an aliphatic group or a substituted aliphatic group.

64. (currently amended) The compound according to claim 22 wherein Z is oxygen; wherein R¹ is hydrogen, -R, -CH₂OR, -CH₂SR, or -CH₂Y; wherein R² is:

~~i) -CO₂H, or an ester, or an amide thereof; or R² is an isostere of said CO₂H; or CH₂CO₂H, or an ester, or an amide thereof; or R² is an isostere of said CH₂CO₂H; and~~

CO₂H, CH₂CO₂H or C₁₋₆ alkyl esters, C₃₋₁₀ cycloalkyl esters, or cholesterol esters thereof; or primary, secondary or tertiary

amides thereof; wherein suitable substituents on the nitrogen of said amides includes one or more C₁₋₆ alkyl groups optionally substituted with N(R)₂ or 5-6 membered heterocyclic rings containing 1-2 heteroatoms; and wherein R is linear or branched C₁₋₁₂ aliphatic; and
wherein R³ is a group having a molecular weight up to 140 Daltons selected from aliphatic, aryl, aralkyl, heterocyclyl or heterocyclylalkyl ring wherein said heterocyclyl ring is a three to nine membered saturated or unsaturated mono-, bi-, or tri-heterocyclic ring system wherein each ring contains up to three heteroatoms selected from O, N, or S.

65. (currently amended) The compound according to claim 22 wherein Z is oxygen;
wherein R¹ is hydrogen, -R, -CH₂OR, -CH₂SR, or -CH₂Y; wherein R² is:

~~i) CO₂H, or an ester, or an amide thereof; or R² is an isostere of said CO₂H; or~~
~~CH₂CO₂H, or an ester, or an amide thereof; or R² is an isostere of said CH₂CO₂H; and~~
CO₂H, CH₂CO₂H or C₁₋₆ alkyl esters, C₃₋₁₀ cycloalkyl esters, or cholesterol esters thereof; or primary, secondary or tertiary amides thereof; wherein suitable substituents on the nitrogen of said amides includes one or more C₁₋₆ alkyl groups optionally substituted with N(R)₂ or 5-6 membered heterocyclic rings containing 1-2 heteroatoms; and wherein R is linear or branched C₁₋₁₂ aliphatic; and
wherein R⁴ and R⁵ taken together with the intervening nitrogen form a mono-, bi- or tricyclic hetero ring system wherein each ring of the system has 5-7 ring atoms;

wherein said ring system is optionally substituted with one or more groups independently selected from halogen, -R⁹, -OR⁹, -OH, -SH, -SR⁹, protected OH (such as acyloxy), phenyl (Ph), substituted Ph, -OPh, substituted -OPh, -NO₂, -CN,

-NH₂, -NHR⁹, -N(R⁹)₂, -NHCOR⁹, -NHCONHR⁹, -NHCON(R⁹)₂,
-NR⁹COR⁹, -NHCO₂R⁹, -CO₂R⁹, -CO₂H, -COR⁹, -CONHR⁹, -CON(R⁹)₂,
-S(O)₂R⁹, -SONH₂, -S(O)R⁹, -SO₂NHR⁹, or -NHS(O)₂R⁹; and

wherein each R⁹ is independently selected from an aliphatic group or a substituted aliphatic group.

66. (previously presented) The compound according to claim 22 wherein Z is oxygen;
wherein R¹ is hydrogen, -R, -CH₂OR, -CH₂SR, or -CH₂Y; wherein R³ is a group having a molecular weight up to 140 Daltons selected from aliphatic, aryl, aralkyl, heterocyclyl or heterocyclylalkyl ring wherein said heterocyclyl ring is a three to nine membered saturated or unsaturated mono-, bi-, or tri-heterocyclic ring system wherein each ring contains up to three heteroatoms selected from O, N, or S; and
wherein R⁴ and R⁵ taken together with the intervening nitrogen form a mono-, bi- or tricyclic hetero ring system wherein each ring of the system has 5-7 ring atoms;

wherein said ring system is optionally substituted with one or more groups independently selected from halogen, -R⁹, -OR⁹, -OH, -SH, -SR⁹, protected OH (such as acyloxy), phenyl (Ph), substituted Ph, -OPh, substituted -OPh, -NO₂, -CN, -NH₂, -NHR⁹, -N(R⁹)₂, -NHCOR⁹, -NHCONHR⁹, -NHCON(R⁹)₂, -NR⁹COR⁹, -NHCO₂R⁹, -CO₂R⁹, -CO₂H, -COR⁹, -CONHR⁹, -CON(R⁹)₂, -S(O)₂R⁹, -SONH₂, -S(O)R⁹, -SO₂NHR⁹, or -NHS(O)₂R⁹; and

wherein each R⁹ is independently selected from an aliphatic group or a substituted aliphatic group.

67. (currently amended) The compound according to claim 22 wherein Z is oxygen;
wherein R² is:

~~i) CO₂H, or an ester, or an amide thereof, or R² is an isostere of said CO₂H; or~~

~~CH₂CO₂H, or an ester, or an amide thereof, or R² is an isostere of said CH₂CO₂H;~~
CO₂H, CH₂CO₂H or C₁₋₆ alkyl esters, C₃₋₁₀ cycloalkyl esters, or cholesterol esters thereof; or primary, secondary or tertiary amides thereof; wherein suitable substituents on the nitrogen of said amides includes one or more C₁₋₆ alkyl groups optionally substituted with N(R)₂ or 5-6 membered heterocyclic rings containing 1-2 heteroatoms; and wherein R is linear or branched C₁₋₁₂ aliphatic;
wherein R³ is a group having a molecular weight up to 140 Daltons selected from aliphatic, aryl, aralkyl, heterocyclyl or heterocyclylalkyl ring wherein said heterocyclyl ring is a three to nine membered saturated or unsaturated mono-, bi-, or tri-heterocyclic ring system wherein each ring contains up to three heteroatoms selected from O, N, or S; and
wherein R⁴ and R⁵ taken together with the intervening nitrogen form a mono-, bi- or tricyclic hetero ring system wherein each ring of the system has 5-7 ring atoms;

wherein said ring system is optionally substituted with one or more groups independently selected from halogen, -R⁹, -OR⁹, -OH, -SH, -SR⁹, protected OH (such as acyloxy), phenyl (Ph), substituted Ph, -OPh, substituted -OPh, -NO₂, -CN, -NH₂, -NHR⁹, -N(R⁹)₂, -NHCOR⁹, -NHCONHR⁹, -NHCON(R⁹)₂, -NR⁹COR⁹, -NHCO₂R⁹, -CO₂R⁹, -CO₂H, -COR⁹, -CONHR⁹, -CON(R⁹)₂, -S(O)₂R⁹, -SONH₂, -S(O)R⁹, -SO₂NHR⁹, or -NHS(O)₂R⁹; and

wherein each R⁹ is independently selected from an aliphatic group or a substituted aliphatic group.

68. (currently amended) The compound according to claim 22 wherein R¹ is hydrogen, -R, -CH₂OR, -CH₂SR, or -CH₂Y;
wherein R² is:

~~i) CO₂H, or an ester, or an amide thereof, or R² is an isostere of said CO₂H; or~~

~~CH₂CO₂H, or an ester, or an amide thereof, or R² is an isostere of said CH₂CO₂H;~~

CO₂H, CH₂CO₂H or C₁₋₆ alkyl esters, C₃₋₁₀ cycloalkyl esters, or cholesterol esters thereof; or primary, secondary or tertiary amides thereof; wherein suitable substituents on the nitrogen of said amides includes one or more C₁₋₆ alkyl groups optionally substituted with N(R)₂ or 5-6 membered heterocyclic rings containing 1-2 heteroatoms; and wherein R is linear or branched C₁₋₁₂ aliphatic;

wherein R³ is a group having a molecular weight up to 140 Daltons selected from aliphatic, aryl, aralkyl, heterocyclyl or heterocyclylalkyl ring wherein said heterocyclyl ring is a three to nine membered saturated or unsaturated mono-, bi-, or tri-heterocyclic ring system wherein each ring contains up to three heteroatoms selected from O, N, or S; and wherein R⁴ and R⁵ taken together with the intervening nitrogen form a mono-, bi- or tricyclic hetero ring system wherein each ring of the system has 5-7 ring atoms;

wherein said ring system is optionally substituted with one or more groups independently selected from halogen, -R⁹, -OR⁹, -OH, -SH, -SR⁹, protected OH (such as acyloxy), phenyl (Ph), substituted Ph, -OPh, substituted -OPh, -NO₂, -CN, -NH₂, -NHR⁹, -N(R⁹)₂, -NHCOR⁹, -NHCONHR⁹, -NHCON(R⁹)₂, -NR⁹COR⁹, -NHCO₂R⁹, -CO₂R⁹, -CO₂H, -COR⁹, -CONHR⁹, -CON(R⁹)₂, -S(O)₂R⁹, -SONH₂, -S(O)R⁹, -SO₂NHR⁹, or -NHS(O)₂R⁹; and

wherein each R⁹ is independently selected from an aliphatic group or a substituted aliphatic group.

69. (currently amended) The compound according to claim 22 wherein Z is oxygen; wherein R¹ is hydrogen, -R, -CH₂OR, -CH₂SR, or -CH₂Y; wherein R² is:

~~i) CO₂H, or an ester, or an amide thereof, or R² is an isostere of said CO₂H; or~~

~~CH₂CO₂H, or an ester, or an amide thereof, or R² is an isostere of said CH₂CO₂H; and~~
CO₂H, CH₂CO₂H or C₁₋₆ alkyl esters, C₃₋₁₀ cycloalkyl esters, or cholesterol esters thereof; or primary, secondary or tertiary amides thereof; wherein suitable substituents on the nitrogen of said amides includes one or more C₁₋₆ alkyl groups optionally substituted with N(R)₂ or 5-6 membered heterocyclic rings containing 1-2 heteroatoms; and wherein R is linear or branched C₁₋₁₂ aliphatic;
wherein R³ is a group having a molecular weight up to 140 Daltons selected from aliphatic, aryl, aralkyl, heterocyclyl or heterocyclylalkyl ring wherein said heterocyclyl ring is a three to nine membered saturated or unsaturated mono-, bi-, or tri-heterocyclic ring system wherein each ring contains up to three heteroatoms selected from O, N, or S; and
wherein R⁴ and R⁵ taken together with the intervening nitrogen form a mono-, bi- or tricyclic hetero ring system wherein each ring of the system has 5-7 ring atoms;

wherein said ring system is optionally substituted with one or more groups independently selected from halogen, -R⁹, -OR⁹, -OH, -SH, -SR⁹, protected OH (such as acyloxy), phenyl (Ph), substituted Ph, -OPh, substituted -OPh, -NO₂, -CN, -NH₂, -NHR⁹, -N(R⁹)₂, -NHCOR⁹, -NHCONHR⁹, -NHCON(R⁹)₂, -NR⁹COR⁹, -NHCO₂R⁹, -CO₂R⁹, -CO₂H, -COR⁹, -CONHR⁹, -CON(R⁹)₂, -S(O)₂R⁹, -SONH₂, -S(O)R⁹, -SO₂NHR⁹, or -NHS(O)₂R⁹; and

wherein each R⁹ is independently selected from an aliphatic group or a substituted aliphatic group.

70. (previously presented) The compound according to claim 22 wherein R² is CO₂H.

71. (previously presented) The compound according to claim 22 wherein R¹ is -CH₂OR, -CH₂SR, or -CH₂Y.

72. (previously presented) The compound according to claim 71 wherein R^1 is $-CH_2Y$.

73. (previously presented) The compound according to claim 72 wherein R^1 is $-CH_2F$.

74. (previously presented) The compound according to claim 22 wherein R^3 is a C_{1-4} alkyl group.

75. (previously presented) The compound according to claim 22 wherein R^1 is $-CH_2F$ and R^3 is a C_{1-4} alkyl group.

76. (previously presented) The compound according to claim 22 wherein R^4 and R^5 taken together with the intervening nitrogen form a ring selected from isoindole, indoline, indazole, purine, dihydropyridine, benzimidazole, imidazole, imidazoline, pyrrole, pyrrolidine, pyrroline, pyrazole, pyrazoline, pyrazolidine, triazole, piperidine, morpholine, thiomorpholine, piperazine, phenothiazine, phenoxazine, dihydrophenazine, dihydrocinnoline, dihydroquinoxaline, tetrahydroquinoline, tetrahydroisoquinoline, dibenzoazepine, dihydro-dibenzoazepine, dihydronaphthyridine, tetrahydronaphthyridine, dihydroacridine, β -carboline, pyrido[4,3-b]indole, 2,3,9-triazafluorene, 9-thia-2,10-diazaanthracene, 3,6,9-triazafluorene, thieno[3,2-b]pyrrole, or dihydrophenanthridine;

wherein said ring is optionally substituted with one or more groups independently selected from halogen, $-R^9$, $-OR^9$, $-OH$, $-SH$, $-SR^9$, protected OH (such as acyloxy), phenyl (Ph), substituted Ph, $-OPh$, substituted $-OPh$, $-NO_2$, $-CN$, $-NH_2$, $-NHR^9$, $-N(R^9)_2$, $-NHCOR^9$, $-NHCONHR^9$, $-NHCON(R^9)_2$, $-NR^9COR^9$, $-NHCO_2R^9$, $-CO_2R^9$, $-CO_2H$, $-COR^9$, $-CONHR^9$, $-CON(R^9)_2$, $-S(O)_2R^9$, $-SONH_2$, $-S(O)R^9$, $-SO_2NHR^9$, or $-NHS(O)_2R^9$; and

wherein each R⁹ is independently selected from an aliphatic group or a substituted aliphatic group.

77. (previously presented) The compound according to claim 76 wherein R⁴ and R⁵ taken together with the intervening nitrogen form a ring selected from carbazole, phenothiazine, indole, indoline, 5H-dibenzo[b,f]azepine, 10,11-dihydro-5H-dibenzo[b,f]azepine, β -carboline, pyrido[4,3-b]indole, 2,3,9-triazafluorene, 9-thia-2,10-diazaanthracene, 3,6,9-triazafluorene, thieno[3,2-b]pyrrole, or dihydrophenanthridine;


wherein said ring is optionally substituted with one or more groups independently selected from halogen, -R⁹, -OR⁹, -OH, -SH, -SR⁹, protected OH (such as acyloxy), phenyl (Ph), substituted Ph, -OPh, substituted -OPh, -NO₂, -CN, -NH₂, -NHR⁹, -N(R⁹)₂, -NHCOR⁹, -NHCONHR⁹, -NHCON(R⁹)₂, -NR⁹COR⁹, -NHCO₂R⁹, -CO₂R⁹, -CO₂H, -COR⁹, -CONHR⁹, -CON(R⁹)₂, -S(O)₂R⁹, -SONH₂, -S(O)R⁹, -SO₂NHR⁹, or -NHS(O)₂R⁹; and

wherein each R⁹ is independently selected from an aliphatic group or a substituted aliphatic group.

78. (previously presented) A pharmaceutical composition comprising a compound according to claim 22 and a pharmaceutically acceptable carrier.

79. (currently amended) A method of treating a caspase-mediated disease selected from an inflammatory disease, osteoarthritis, rheumatoid arthritis, psoriasis, ~~glomerulonephritis,~~ graft vs host disease, inflammatory bowel disease, sepsis, septic shock, ~~burns,~~ stroke, cerebral ischemia, ~~traumatic brain injury,~~ neurological damage due to stroke, ~~spinal cord injury,~~ ~~amyotrophic lateral sclerosis,~~ ~~multiple sclerosis,~~ myocardial infarct, myocardial ischemia, atherosclerosis, acute respiratory failure, adult respiratory

distress syndrome, ~~pancreatitis, various forms of liver and renal disease, acute renal failure, an excess dietary alcohol intake disease, chronic active hepatitis, hepatitis B, hepatitis-C, or coronary artery bypass graft or a treatment for complications associated with coronary bypass grafts~~ in a patient in need thereof ~~that is alleviated by treatment with a caspase inhibitor, comprising administering to a said patient in need of such a treatment~~ a therapeutically effective amount of a compound according to formula I:



wherein:

Z is oxygen or sulfur;

R¹ is hydrogen, -CHN₂, -R, -CH₂OR, -CH₂SR, or -CH₂Y;

R is a C₁₋₁₂ aliphatic, aryl, aralkyl, heterocyclyl, or heterocyclylalkyl ring, wherein each of these groups is optionally substituted, and wherein said heterocyclic ring is a three to nine membered saturated or unsaturated mono-, bi-, or tri-heterocyclic ring system wherein each ring contains up to three heteroatoms selected from O, N, or S;
Y is an electronegative leaving group selected from F, Cl, Br, I, arylsulfonyloxy, alkylsulfonyloxy, trifluoromethanesulfonyloxy, OR', SR', -OC=O(R'), or -OPO(R⁶)(R⁷);

wherein R' is an aliphatic group, an aryl group, an aralkyl group, a carbocyclic group, an alkyl carbocyclic group, a heterocyclic group, or an alkyl heterocyclic group;

wherein R⁶ and R⁷ are independently selected from R or OR;
R² is CO₂H, CH₂CO₂H or C₁₋₆ alkyl esters, C₃₋₁₀ cycloalkyl esters, or cholesterol esters thereof; or primary, secondary or tertiary amides thereof; wherein suitable substituents on the nitrogen of said amides includes one or more C₁₋₆ alkyl

groups optionally substituted with $N(R)_2$ or 5-6 membered heterocyclic rings containing 1-2 heteroatoms; and wherein R is linear or branched C_{1-12} aliphatic;

R^3 is selected from H, a side chain of a natural α -amino acid, or a substituted or unsubstituted group having a molecular weight up to about 140 Daltons selected from aliphatic, aryl, aralkyl, heterocyclyl or heterocyclylalkyl ring wherein said heterocyclyl or heterocyclylalkyl ring is a three to nine membered saturated or unsaturated mono-, bi-, or tri-heterocyclic ring system wherein each ring contains up to three heteroatoms selected from O, N, or S; and R^4 and R^5 taken together with the intervening nitrogen form a mono-, bi- or tricyclic hetero ring system having 1-6 heteroatoms selected from nitrogen, oxygen or sulfur;

wherein said ring system is optionally substituted with one or more groups independently selected from halogen, $-R^9$, $-OR^9$, $-OH$, $-SH$, $-SR^9$, protected OH (such as acyloxy), phenyl (Ph), substituted Ph, $-OPh$, substituted $-OPh$, $-NO_2$, $-CN$, $-NH_2$, $-NHR^9$, $-N(R^9)_2$, $-NHCOR^9$, $-NHCONHR^9$, $-NHCON(R^9)_2$, $-NR^9COR^9$, $-NHCO_2R^9$, $-CO_2R^9$, $-CO_2H$, $-COR^9$, $-CONHR^9$, $-CON(R^9)_2$, $-S(O)_2R^9$, $-SONH_2$, $-S(O)R^9$, $-SO_2NHR^9$, or $-NHS(O)_2R^9$;

wherein each R^9 is independently selected from an aliphatic group or a substituted aliphatic group; wherein the optional substituents on said C_{1-12} aliphatic group or aryl, aralkyl, heterocyclyl, or heterocyclylalkyl ring is independently selected from, from halogen, $-R^{11}$, $-OR^{11}$, $-OH$, $-SH$, $-SR^{11}$, acyloxy, substituted or unsubstituted Ph or OPh, $-NO_2$, $-CN$, $-NH_2$, $-NHR^{11}$, $-N(R^{11})_2$, $-NHCOR^{11}$, $-NHCONHR^{11}$, $-NHCON(R^{11})_2$, $-NR^{11}COR^{11}$, $-NHCO_2R^{11}$, $-CO_2R^{11}$, $-CO_2H$, $-COR^{11}$, $-CONHR^{11}$, $-CON(R^{11})_2$, $-S(O)_2R^{11}$, $-SONH_2$, $-S(O)R^{11}$, $-SO_2NHR^{11}$, $-NHS(O)_2R^{11}$, $=O$, $=S$, $=NNHR^{11}$, $=NNR^{11}_2$, $=N-OR^{11}$, $=NNHCOR^{11}$, $=NNHCO_2R^{11}$, $=NNHSO_2R^{11}$, or $=NR^{11}$; and

wherein each R^{11} is independently selected from a C_{1-12} aliphatic group or a substituted C_{1-12} aliphatic group.

80. (canceled)

81. (currently amended) A method for the preservation of cells in an organ for transplant or in a blood product said method comprising the step of bathing the cells in a solution of a compound ~~of formula I~~ according to claim 22.